Skip to main content
. 2018 Apr 16;131(24):2720–2729. doi: 10.1182/blood-2018-02-831156

Table 4.

Hazard of all-cause late mortality among 2-year survivors of autologous BMT in childhood, for the entire cohort and lymphoma and neuroblastoma survivors

Variables Multivariable analysis, entire cohort Multivariable analysis, HL + NHL Multivariable analysis, neuroblastoma
HRadj 95% CI P HRadj 95% CI P HRadj 95% CI P
Sex
 Male 1.00 1.00 1.00
 Female 1.82 1.19-2.78 .006 1.69 0.76-3.85 .2 3.33 1.35-8.33 .008
Race/ethnicity
 Non-Hispanic white 1.00 1.00 1.00
 Hispanic 1.08 0.59-1.99 .8 1.85 0.67-5.10 .2 0.77 0.21-2.76 .7
 Non-Hispanic black 1.37 0.58-3.26 .5 1.89 0.47-7.71 .4
 Other 0.38 0.05-2.76 .3 9.66 0.89-105.0 .06
 Unknown 0.51 0.08-3.69 .5
 Age at BMT* 1.03 0.98-1.07 .3 0.96 0.89-1.04 .3 1.16 1.08-1.25 <.001
Year of BMT
 <1990 1.00 1.00 1.00
 1990-1999 0.47 0.26-0.86 .01 0.82 0.30-2.24 .7 0.24 0.05-1.32 .1
 2000-2010 0.33 0.15-0.73 .006 0.15 0.04-0.61 .007 1.15 0.17-7.62 .9
Source of stem cells
 Bone marrow 1.00 1.00 1.00
 PBSCs/cord blood 1.29 0.72 2.30 .4 1.12 0.44-2.85 .9 0.95 0.14-6.60 1.0
Primary diagnosis
 HL 1.00 1.00
 NHL 1.15 0.44-3.01 .8 1.39 0.43-4.49 .6
 ALL 2.40 0.91-6.32 .08
 AML 0.36 0.13-1.01 .05
 Neuroblastoma 2.36 0.98-5.71 .06
 Other malignant disease 2.29 1.06-4.92 .03
Disease status at BMT
 Standard risk of relapse 1.00 1.00
 High risk of relapse 1.49 0.82-2.74 .2 1.53 0.68-3.46 .3
Conditioning regimen
 TBI
  No 1.00 1.00 1.00
  Yes 0.58 0.29-1.16 .1 0.34 0.11-1.03 .06 1.39 0.23-8.63 .7

HRadj, hazard ratio, adjusted for all given variables in table.

*

Age included in the model as a continuous variable.

Includes 25 Ewing sarcomas, 11 Wilms tumor, 9 CNS tumors, 4 desmoplastic small round cell tumors, 6 soft tissue sarcoma, 1 ovarian tumor, 1 hepatoblastoma, and 1 multiple myeloma.

Standard risk: first or second complete remission after acute leukemia or lymphoma; all others high risk.